Semaglutide vs Liraglutide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Metabolic / GLP-1 Agonist |
| Evidence Rating | A — FDA Approved | A — FDA Approved |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | FDA-approved (Victoza for T2D, Saxenda for obesity) |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying promoting prolonged fullness, and redu... | Liraglutide binds to GLP-1 receptors on pancreatic β-cells, increasing intracellular cAMP and triggering glucose-dependent insulin secretion. It suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake and increase satiety. A fatty acid (C1... |
| Half-Life | ~160–168 hours (~7 days) | ~13 hours |
| Bioavailability | ~89% SC; lower oral bioavailability (requires empty stomach) | ~55% SC |
| Molecular Weight | ~4113.6 g/mol | ~3,751 g/mol |
| WADA Status | Not Prohibited | Not Prohibited |
| Research Half-Life | ~160–168 hours (~7 days) | ~13 hours |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved (Ozempic, Wegovy, Rybelsus). Additional approvals: MASH with fibrosis (Aug 2025), oral 25 mg for weight management (late 2025). 135+ warning letters issued to GLP-1 compounders; proposed permanent ban on 503B GLP-1 compounding. | FDA-approved: Victoza (T2D, 2010), Saxenda (obesity, 2014). Prescription only. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Semaglutide | Liraglutide |
|---|---|---|
| Purity Standard | ≥98% | — |
| CAS Number | 910463-68-2 | — |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ | — |
| Available Formats | 10mg | — |
| Batch COAs Published | — | — |
| Stock Status | In stock | — |
Availability at Volta Peptides
Semaglutide 10mg
≥98% purity · HPLC verified · In stock
$49
Liraglutide
Not currently stocked at Volta Peptides.
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.